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Short Communication
Transcriptional impairment of b-catenin/E-cadherin complex is not
associated with b-catenin mutations in colorectal carcinomas
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We report the absence of b-catenin mutations in 63 sporadic colorectal carcinomas (SCRCs) with demonstrated decreased
b-catenin and E-cadherin mRNA expression and E-cadherin protein expression in a subset of carcinomas examined, suggesting
that b-catenin mutations are an extremely rare phenomenon in SCRCs and are not responsible for the transcriptional impairment
of the b-catenin/E-cadherin adhesion complex observed in these tumours.
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b-catenin is a 92-kDa multifunctional protein that, when localised
in the membrane, links the intracellular part of the E-cadherin
complex to the actin cytoskeleton, a step critical to morphogenesis
and the maintenance of tissue architecture (Aberle et al, 1994).
Alternatively, through Wnt signalling-mediated stabilisation, b-
catenin may act as a downstream transcriptional transactivator of
several target genes (Barth et al, 1997). Alterations in b-catenin
protein expression levels and genetic rearrangements located in b-
catenin exon 3 have been shown to contribute to the malignant
character of various carcinomas and are likely to affect both
intercellular adhesion and signal transduction, which are believed
to be two independent functions of the b-catenin protein (Fujimori
et al, 2001). The rarity of mutations within b-catenin exon 3 has
been previously documented in ulcerative colitis-related neoplastic
progression (Nilbert et al, 2001) and in rectal cancer (Aust et al,
2002) but, to the best of our knowledge, not in SCRCs. In fact, the
variable immunohistochemical studies performed suggest that the
observed accumulation in b-catenin protein is probably because of
genomic alterations in b-catenin coding regions and, in particular,
b-catenin exon 3. This study rules out significantly this possibility,
indicating that other mechanisms (i.e. those that might be involved
in the regulation of the b-catenin mRNA level) may play a role in
the observed protein accumulation. Furthermore, the effect of
these genetic alterations on the transcriptional activity of the b-
catenin/E-cadherin adhesion complex is not yet known. Within
this context, we investigated the possible association of b-catenin
mutations in exon 3 with the b-catenin/E-cadherin adhesion
complex transcriptional activity by determining their mRNA levels
and the levels of E-cadherin protein expression in a subset of these
carcinomas.
MATERIALS AND METHODS
Tumour tissues and control samples
A total of 63 sporadic colorectal adenocarcinomas and adjacent
normal tissues at least 2cm from the distal negative margin of the
tumour were obtained from surgically treated patients at Nikaia
Hospital, Athens, Greece. None of the patients received irradiation
preoperatively.
PCR-single-strand conformation polymorphism (SSCP)
and b-catenin exon 3 genomic rearrangements
cDNA from 63 tumour specimens was amplified for SSCP
screening to detect b-catenin nucleotide substitutions as pre-
viously described (Iwao et al, 1998). The same primer set was used
to amplify genomic DNA corresponding to DNA sequences in
exons 2 and 4 to detect genomic rearrangements involving exon 3
and for automated sequencing (Figure 1A).
Multiplex RT–PCR analysis
Owing to sample unavailability, RT–PCR analysis for b-catenin
and E-cadherin was carried out in a subset of 37 SCRCs from the
same series. cDNA primers and amplification conditions for b-
catenin and E-cadherin have been previously described (Oda et al,
1994; Iwao et al, 1998). 18S rRNA primers were used to amplify the
invariant endogenous control (Quantum RT–PCR, Ambion, USA).
A two-fold increase or decrease was considered as the cutoff value.
Since identical multiplex quantitative reactions may still exhibit
some degree of variation, all reactions were performed in
duplicates. The level of the product from b-catenin and/or E-
cadherin gene was normalised against 18S rRNA as follows: all raw
data were first transformed to a logarithmic scale. The latter makes
variation of band intensities and ratios of band intensities
independent of the absolute magnitude and evens out highly
skewed distributions. Following log transformation, we divided,
for each sample, the signal obtained for the E-cadherin-specific Revised 8 October 2002; accepted 17 October 2002
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yamplicon by the signal obtained for the 18S rRNA amplicon. This
yielded a corrected relative log ratio that was the weighted average
from each pair of duplicate PCR reactions for each gene-specific
product in each sample. Log ratio values were then compared
between samples for an estimate of the relative expression of target
RNA in these samples. Negative and positive controls for b-
catenin, E-cadherin and 18S rRNA amplicons were included in
each amplification.
Immunohistochemistry (IHC)
E-cadherin immunohistochemical analysis was performed with the
antibody (Ab) H-108 (class: rabbit polyclonal; epitope: residues
600–707; Santa Cruz, CA, USA) in formalin-fixed paraffin-
embedded tissue sections from the same subset of 37 SCRCs as
previously described (Ilyas et al, 1997). The extent of staining was
compared to normal paired tissue sections and IHC evaluation was
performed as follows: grade 0: 0% of stained cells; grade 1: 1–30%;
grade 2: 31–50%; grade 3: 450%. Incubating paraffin sections in
the absence of the primary antibody tested the specificity of
E-cadherin primary Ab H-108.
Statistical methods
Statistical analysis was performed using the two-sided Kruskal–
Wallis test validated by Fisher’s exact test where appropriate.
Statistical significance was set at Po0.03.
RESULTS AND DISCUSSION
The clinical and pathological features for the subset of 37 SCRC
patients (20 males and 17 females, mean age: 67.3 years; range: 53–
84 years) are shown in Table 1(A). The SSCP screening on b-
catenin exon 3 did not demonstrate any nucleotide substitutions or
polymorphisms in all 63 SCRCs examined (Figure 1B). Similarly,
PCR-amplified experiments using genomic DNA with the same
primer set corresponding to DNA sequences in exons 2 and 4 did
not detect any PCR products smaller than the expected 931 base-
pair (bp) product (Figure 1A). These results indicate that b-catenin
mutations and/or splicing changes comprise an infrequent
phenomenon in SCRCs, revealing the possibility that various
regulatory mechanisms acting on b-catenin mRNA expression may
determine its oncogenic potential.
It was surprising that subsequent RT–PCR analysis in a subset
of 37 SCRCs demonstrated a more than two-fold decreased
expression of b-catenin mRNA in 24 out of 37 (65%) of the
carcinomas examined (Table 1(A), Figure 1C). Few studies have
focused on the mutational analysis of the b-catenin gene
demonstrating an altered IHC expression of b-catenin without
genetic alterations (Rimm et al, 1999; Bilim et al, 2000). However,
none of these studies confirmed b-catenin expression at the mRNA
level and there might be a possibility that the reported changes in
antigen availability have occurred as a result of post-translational
modification. The decreased expression of b-catenin at the mRNA
level may indicate a high turnover that keeps up the steady-state
levels of b-catenin expression at the protein level. Alternatively, it
may point out a b-catenin epigenetically associated transcriptional
silencing similar to that previously reported for E-cadherin
inactivation in SCRCs (Garinis et al, 2002). Therefore, the
possibility remains that for b-catenin, promoter hypermethylation
could be as critical for, and possibly as frequent, in SCRC evolution
as mutations in critical coding regions.
A paralleled decreased expression of E-cadherin mRNA was
demonstrated in 25 out of 37 of the carcinomas (68%), and this
was followed by a comparable decrease of E-cadherin IHC
expression (grade I) in 21 out of 37 (57%) of SCRCs (Table 1a,
Figures 1C and D). E-cadherin IHC expression (grade I) was
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Figure 1 (A) Schematic representation of the primer set used to amplify
genomic DNA and cDNA of the b-catenin gene. (B) SSCP analysis of the
b-catenin exon 3. Arrowheads indicate single-stranded (ss) and double-
stranded (ds) DNA. (C) RT–PCR analysis of the b-catenin and E-cadherin
mRNA levels. P1 and P2 represent 18S rRNA and b-catenin or E-cadherin
positive controls, respectively. As an example, samples 6, 7 and 13
demonstrated a decrease of mRNA expression in both E-cadherin and b-
catenin followed by a parallel decrease in E-cadherin protein expression as
depicted in D.( D) E-cadherin immunohistochemical detection in SCRCs
in tumour (T) and adjacent normal tissue (N) sections. Samples N6,
N7, N13 and N24 demonstrated a uniform expression of E-cadherin
protein along intercellular borders in normal colonic mucosa. Samples T6,
T7, T13 and T24 exhibited a decreased and diffused cytoplasmic
staining with occasional intensified immunoreactivity at the luminal
surface.
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expression profiles in 17 out of 37 (42.5%) and 23out of 37 (62%),
respectively (Table 1(B)). The fact that b-catenin has two different
functions, nuclear signalling and cadherin-mediated adhesion at
the plasma membrane, raises the possibility that cadherins could
transduce a signal to the nucleus via b-catenin. In addition, recent
data suggest that in the cytosol, b-catenin may bind to GSK-3b
(Wnt regulatory pathway), APC, and Axin, while in the nucleus
binding to TCF leads to promotion of gene transcription
(Alexander et al, 2002). The Wnt transduction pathway induces
the nuclear translocation of b-catenin and has a major role in cell
fate determination. Tight somatic regulation of this signal is
essential, and uncontrolled accumulation of b-catenin in the
nucleus may lead to tumour initiation in the adult organism.
Kielman et al (2002) have provided genetic and molecular evidence
that the ability and sensitivity of embryonic stem cells to
differentiate into the three germ layers is inhibited by increased
dosages of b-catenin made available for Wnt signalling by specific
APC defects. Furthermore, b-catenin may participate in ubiquitina-
tion and subsequent degradation pathways (Alexander et al, 2002).
All data presented above point out b-catenin as a major sensor of an
array of signals and imply that differentiation defects in tissue
homeostasis are likely to underlie tumorigenesis because of
inactivation of the APC/b-catenin signalling pathway. Since in this
study, loss of mRNA expression in one of the components of this
adhesion complex was often paralleled by a similar pattern of
transcriptional impairment in the other (i.e. E-cadherin), these
results point out an additional possible physiological association
between E-cadherin expression and the b-catenin signalling path-
ways described above. However, it is not yet known whether
changes in E-cadherin mRNA and/or protein expression levels may
affect b-catenin signalling and our study cannot rule out the
possibility of cytoplasmic b-catenin stabilisation at the protein level.
Both decreased b-catenin and E-cadherin gene expression were
significantly associated with the presence of lymph node metastases
(LN) (P¼0.018) in 20 out of 37 (54%) and in 22 out of 37 (59%)
(P¼0.001) of the carcinomas examined, respectively. Similarly,
a significant inverse association was observed between decreased
Table 1 b-catenin and E-cadherin mRNA expression in association with patients’ clinicopathological features and E-cadherin protein
immunohistochemical detection
(A)
b-catenin mRNA E-cadherin mRNA E-cadherin IHC
ND (n=7) 2 (n=24) + (n=6) ND (n=6) 2 (n=25) + (n=6) I (n=21) II (n=10) III (n=6)
Gender
Females 2 11 2 3 12 2 6 4 3
Males 5 13 4 3 13 4 15 6 3
Location
Right 2 8 2 2 8 3 8 6 2
Left 2 7 2 1 7 2 10 3 3
Rectum 3 9 2 3 10 1 3 1 1
LN
No 5 4 3 3 3 5 1 4 2
Yes 2 20 3 3 22 1 20 6 3
(P=0.018) (P=0.001) (P=0.012)
Grade
Well/mod 2 9 2 1 13 1 12 1 2
Poor 5 15 4 5 12 5 9 9 4
Stage
A1 0 0 0 1 0 1 0 3
B1-B2 2 8 2 1 6 4 4 4 2
C1-C2 4 16 4 5 18 2 16 6 1
Tumour Size
0–3 3 4 4 2 3 3 11 3 2
3.1–6 4 20 2 3 18 2 7 7 2
6.1–11 0 2 0 0 2 1 4 0 2
(B)
b-catenin mRNA E-cadherin mRNA
ND 2 +N D 2 +
E-cadherin IHC
I 3 17 4 2 23 0
(P=0.003) (P=0.001)
II 3 6 3 2 4 4
III 0 1 2 0 1 1
ND=no difference in mRNA expression between normal and tumour sample; LN=lymph node metastasis; mod=moderate; A-C2=Astler–Coller’s classification.
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20 out of 37 (54%) of these carcinomas. The demonstrated
impairment of b-catenin/E-cadherin adhesion and its association
with LN metastasis (Table 1) suggests that the inactivation of the E-
cadherin/b-catenin system through multiple mechanisms and the
subsequent suppression of cell-cell adhesiveness may trigger the
release of cancer cells from the primary tumour foci and confer
invasive properties on the primary tumour mass.
In essence, this study shows that the mutations within b-catenin
exon 3 are an infrequent event in SCRCs and that b-catenin genetic
alterations are not responsible for the demonstrated loss of b-
catenin/E-cadherin transcriptional activity.
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